Nebivolol Zentiva (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic receptor blocker used in the management of cardiovascular conditions.

• Essential hypertension: provides sustained reduction of high blood pressure.
• Secondary hypertension: assists in controlling blood pressure when caused by another condition.
• Isolated systolic hypertension: lowers systolic pressure to reduce cardiovascular risk.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and myocardial contractility, which reduces cardiac output. In addition, it stimulates endothelial nitric oxide release, causing vasodilation and further lowering peripheral vascular resistance, thereby contributing to blood pressure reduction.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general feeling of tiredness.
• Nausea: upset stomach or urge to vomit.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Atrioventricular block: impaired electrical conduction in the heart.
• Bronchospasm: tightening of airway muscles, especially in asthmatic patients.
• Hypotension: dangerously low blood pressure.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Anaphylactic reaction: rare severe allergic response.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: ensure adequate control and avoid excessive lowering.
• Heart rate assessment: watch for bradycardia, especially in patients with conduction disorders.
• Asthma/COPD caution: use carefully in patients with reactive airway disease.
• Discontinuation: avoid abrupt withdrawal to prevent rebound hypertension.
• Renal impairment: adjust therapy based on renal function.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Non‑selective beta blockers: may cause additive bradycardia.
• Calcium channel blockers (verapamil, diltiazem): increase nebivolol plasma levels.
• Strong CYP2D6 inhibitors (paroxetine, fluoxetine): reduce metabolism, raising drug exposure.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, risking hypotension.

• ACE inhibitors or ARBs: combined use may lead to excessive blood pressure reduction.
• Antidiabetic agents: nebivolol may mask hypoglycemia symptoms.